Jpmorgan Chase & CO Lumos Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Lumos Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 13 shares of LUMO stock, worth $56. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13
Previous 13
-0.0%
Holding current value
$56
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LUMO
# of Institutions
31Shares Held
2.2MCall Options Held
0Put Options Held
0-
Private Advisor Group, LLC745KShares$3.23 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY362KShares$1.57 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$1.06 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny214KShares$927,9520.0% of portfolio
-
Jefferies Group LLC New York, NY121KShares$523,6250.01% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $36.4M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...